Alto Neuroscience, Inc. financial data

Symbol
ANRO on NYSE
Location
650 Castro Street, Suite 450, Mountain View, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.69K %
Debt-to-equity 20.7 %
Return On Equity -44.8 % +46%
Return On Assets -37.1 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27.1M shares +0.44%
Common Stock, Shares, Outstanding 27.1M shares +0.45%
Weighted Average Number of Shares Outstanding, Basic 27.1M shares +0.59%
Weighted Average Number of Shares Outstanding, Diluted 27.1M shares +0.59%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 47M USD +15.2%
General and Administrative Expense 23.3M USD +72.9%
Operating Income (Loss) -70.2M USD -29.6%
Nonoperating Income (Expense) 5.38M USD +22.2%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -64.9M USD -30.2%
Earnings Per Share, Basic -2 USD/shares +65.4%
Earnings Per Share, Diluted -2 USD/shares +65.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 148M USD -23.6%
Other Assets, Current 23K USD -84.7%
Assets, Current 150M USD -23.3%
Property, Plant and Equipment, Net 2.31M USD +60.1%
Operating Lease, Right-of-Use Asset 4.65M USD
Assets 158M USD -20%
Accounts Payable, Current 1.67M USD -9.33%
Employee-related Liabilities, Current 2.79M USD +11.7%
Accrued Liabilities, Current 6.46M USD +13.6%
Liabilities, Current 8.13M USD -17.4%
Operating Lease, Liability, Noncurrent 4.21M USD
Liabilities 34.5M USD +96%
Accumulated Other Comprehensive Income (Loss), Net of Tax 31K USD
Retained Earnings (Accumulated Deficit) -171M USD -61%
Stockholders' Equity Attributable to Parent 123M USD -31.4%
Liabilities and Equity 158M USD -20%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.6M USD -50.7%
Net Cash Provided by (Used in) Financing Activities 9.13M USD -93.2%
Net Cash Provided by (Used in) Investing Activities -24K USD +89.3%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 27.1M shares +0.45%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -7.48M USD -106%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 148M USD -23.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 311K USD +25.4%
Deferred Tax Assets, Valuation Allowance 37.4M USD +62.5%
Deferred Tax Assets, Gross 39.4M USD +69.9%
Operating Lease, Liability 5.39M USD +4209%
Payments to Acquire Property, Plant, and Equipment 24K USD -89.3%
Lessee, Operating Lease, Liability, to be Paid 7.07M USD
Operating Lease, Liability, Current 973K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.22M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 917K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +112%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.68M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.46M USD
Deferred Tax Assets, Operating Loss Carryforwards 12.1M USD +14.7%
Preferred Stock, Shares Issued 0 shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.5M USD
Operating Lease, Payments 0 USD
Additional Paid in Capital 295M USD +2.93%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 576K USD +50%
Deferred Tax Assets, Net of Valuation Allowance 1.97M USD +1246%
Share-based Payment Arrangement, Expense 7.54M USD +44.6%